By Abigail Townsend
Date: Thursday 26 Mar 2026
(Sharecast News) - Oxford Biomedica posted a surge in annual revenues on Thursday, but warned it was on track to swing to an interim loss this year before returning to growth in the second half.
By Michele Maatouk
Date: Wednesday 25 Feb 2026
(Sharecast News) - Oxford Biomedica shares slumped on Wednesday after Swedish private equity firm EQT said it was not planning to make an offer for the gene and cell therapy company.
By Iain Gilbert
Date: Tuesday 24 Feb 2026
(Sharecast News) - Contract development and manufacturing firm Oxford Biomedica said on Tuesday that it expects to report a strong rise in full year revenues, but signalled that underlying profitability would only be modest despite a one‑off boost from its US acquisition.
| Currency | UK Pounds |
| Share Price | 629.00p |
| Change Today | 1.00p |
| % Change | 0.16 % |
| 52 Week High | 913.00 |
| 52 Week Low | 307.00 |
| Volume | 58,113 |
| Shares Issued | 121.01m |
| Market Cap | £761.16m |
| Beta | 0.03 |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 5 |
| Buy | 2 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 10 |

| No dividends found |
| Time | Volume / Share Price |
| 13:42 | 0 @ 629.00p |
| 13:42 | 3 @ 629.00p |
| 13:40 | 0 @ 629.00p |
| 13:40 | 1 @ 629.00p |
| 13:37 | 4 @ 626.51p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research